IGF1 and cancer: This is the first study to adopt an outcome-wide approach to the investigation of IGF-I and risk of 25 common conditions (other than cancer); this comprehensive approach allowed us to assess and compare the effect sizes of multiple outcomes within the UK Biobank and reduce outcome-selection bias.